B Greg Brown, Xue-Qiao Zhao, Dianne E Sacco, John J Albers Treatments designed to diminish the clinical impact of coronary artery disease (CAD) have two fundamental goals. The first goal is to reduce the symptomatic limitations imposed by an obstructed arterial blood supply which is unable to meet the peak oxygen demands of the myocardium. Vascular supply may be insufficient because of a fixed flow-limiting coronary narrowing, abnormal epicardial vessel tone, intermittent arterial vasospasm, microvascular dysfunction, or inadequate development of collateral vessels. Certain medical approaches presently palliate symptoms by favourably altering the imbalance between oxygen supply and demand. The goal of symptom relief may, alternatively, be attained through more direct structural or physiological changes or both that improve the diminished vascular flow reserve. These include relaxation of excess vasoconstrictor tone, development of collateral vessels, or reduction ("regression") in the severity of flow-limiting stenosis. Regression has not been universally accepted as a possible mechanism for symptom relief. We review the evidence supporting the occurrence of regression and its promotion by lipid lowering.
The second fundamental goal of treatment in CAD is to prevent the anticipated progression to a clinical event such as cardiac death, non-fatal myocardial infarction, or worsening angina requiring bypass surgery or angioplasty. Such ischaemic events commonly occur suddenly (even after a recent "perfectly normal" treadmill test) suggesting an abrupt transition in the severity of arterial obstruction. We also discuss the ways in which structural disruption of the atherosclerotic plaque may lead to abrupt worsening of arterial obstruction and, commonly, a clinical event. New data are presented that indicate a linkage between lipid lowering and stabilisation of plaque structure. They support the hypothesis that lipid-lowering treatment prevents clinical events by causing selective regression of the lipid-rich subgroup of plaques which are vulnerable to fissuring, ulceration, and haemorrhage.
Regression of coronary obstruction Arteriographers occasionally observe the reopening of a previously obstructed coronary artery, presumably by the lysis of an occlusive thrombus. Furthermore, ordinary lesions are sometimes seen to improve in a later arteriogram. Thus the important question is not "does it happen clinically?" (it does), but "can we promote regression of sufficiently great magnitude and frequency so that it favourably alters the clinical course of the disease?" As yet there is not a consensus but encouraging evidence is emerging.
EXPERIMENTAL OBSERVATIONS
Convincing evidence that atherosclerosis can regress with lipid lowering has come from studies in cholesterol-fed primates. 1-5 After prolonged exposure to a cholesterol-rich "atherogenic" diet there are large increases in coronary artery collagen (3 x ), elastin (4 x ), and cholesterol (7 x, mostly esterified The Lifestyle Heart Trial enrolled 48 patients with documented clinical coronary disease.'6 Average baseline LDL cholesterol, HDL cholesterol, and triglycerides were 41, 1 3, and 2-4 mmol/l respectively. The subset randomised to treatment received intense counselling and support in adopting a vegetarian diet with less than 10% of calories as fat. They were also counselled about relaxation techniques and were encouraged to pursue a moderate exercise regimen. In the treated group LDL cholesterol fell 37% and HDL fell 3%. The angiographic interval was one year. Familial Atherosclerosis Treatment Study (FA TS) 17 -One hundred and forty six patients with angiographic coronary disease, raised apolipoprotein B, and a positive family history of coronary heart disease were enrolled. Baseline LDL cholesterol, HDL cholesterol, and triglycerides were 4 9, 1 0, and 2-4 mmol/l, respectively. Treatment was randomly assigned; the control group received professional dietary counselling and also colestipol (30 g daily) if the LDL cholesterol was greater than the 90th percentile for age. Two intensively treated groups received dietary counselling, colestipol, and either lovastatin 40 mg daily or niacin 4 g daily, with a specified dose increase for failure to achieve the target of LDL cholesterol < 3-1 mmol/l. In the niacin/colestipol group, LDL cholesterol fell 32% and HDL rose 43%. In the lovastatin/colestipol group, LDL fell 46% and HDL rose 15%. The angiographic interval was 2-5 years (table) In the NHLBI II, CLAS, CLAS II, and POSCH trials change in arterial obstruction was assessed visually by panels of experts blinded to patient identity, randomisation, and temporal sequence of the film pair. In the remainder of the trials a similarly blinded analysis incorporated techniques of computer-assisted quantitative arteriography.7 21 In only four of these eight trials of lipid-lowering therapy was there an entry requirement for even modest hyperlipidaemia. Despite the diversity among these studies in clinical presentation, lipid entry requirements, treatment regimens and methods for arteriographic analysis, their outcomes, summarised in the table, are surprisingly consistent. Each study demonstrated an arterial benefit from treatment, be it diet or diet supplemented by ileal bypass surgery or by other lifestyle changes or by lipid-altering drugs. As a generalisation from these results, less than a twelfth of the control group patients were found to have favourable changes in arterial obstruction ("regression") during the study period. By contrast, more than a quarter of treated patients were found to have overall regression (a 3-4-fold increase). The table shows that mean estimates of coronary disease severity per patient worsened (progressed) by about 3% stenosis among the controls whereas there was an improvement (regression) by 1-2% stenosis among the treated patients. In nearly every study the frequency of cardiovascular events was reduced substantially by treatment The landmark Lipid Research Clinics Program coronary primary prevention trial22 established that modest LDL cholesterol reduction promoted a significant reduction in clinical coronary events, but not in total mortality. Importantly, the magnitude of cardiovascular benefit correlated with the amount of LDL cholesterol reduction. The Helsinki Heart Study,23 also with modest LDL change, achieved a significant reduction in total cardiac events, but not mortality. The Coronary Drug Project, when updated about eight years after its completion, showed an 11% reduction in total mortality among those treated with niacin. 24 Additional evidence that clinical events are decreased by lipid-lowering therapy is seen in the table. Many of these recent trials have used more potent lipid-lowering agents or combination treatments. As a result the magnitude of benefit is correspondingly greater. Each trial reports events somewhat differently. In general, when reported, we have included cardiac death, confirmed myocardial infarction, and progressive, medically refractory ischaemia requiring revascularisation (bypass or angioplasty) among the composite of clinical events. Figure 2 shows data from the FATS trial. It is thus clear from the table and fig 2 and from the primary prevention trials that clinical cardiovascular events are reduced by lipid-lowering therapy. The magnitude of reduction in clinical risk seems out of keeping with the average 1-2%S diameter stenosis regression in lesion severity and with the fact that only about 12% of all intensively treated lesions actually regress by a measurable amount. To understand how regression of a small number of lesions might result in a roughly 60% (range 25%-89%) reduction in the frequency of clinical events, we must understand the series of events in the plaque that turn a stable quiescent lesion into an unstable ischaemia-provoking culprit lesion. DETERMINANTS occur under these circumstances.292h Specifically, when the lesion precipitating a myocardial infarct has, by chance, been visualised on a recent angiogram, its preinfarct severity averages 50% stenosis, and it will not usually possess features indicating that it is destined soon to become occluded.2526 A second, histological, insight is that most ischaemic coronary events are linked to a "culprit" lesion with one or more of the following features at histological examination: (a) a fissured, torn, or vented fibrous cap; (b) mural thrombus adherent at the site of the fissure; (c) bleeding into the core lipid region; and (d) severe arterial obstruction secondary to the composite mass of expanded plaque and thrombus. Figure 3 shows angiographic images of a plaque that has become unstable and caused a myocardial infarction. How does an "ordinary" coronary lesion become so disruptively transformed? Serial histological sectioning of such an acutely occluded coronary lesion will inevitably show a site of fissuring of the fibrous cap that overlies the lipid-rich core of the atheroma.27 28 This fissure is the nidus from which occlusive thrombus has grown, and it can be the point of entry of haemorrhage into the plaque. Certain plaque characteristics increase the risk of disruption. In fibrous caps that fissure, the foam cell density is greater than that in intact caps.27-29 Furthermore, the most common site of fissuring occurred at the shoulder of an eccentric lipid-rich plaque, a location of high foam cell density29 and also high circumferential shear stress, according to a computer model of repeated cyclic distension of the diseased arterial cross section. Thus the histological features of a large lipid pool and of an abundance of lipid laden foam cells in the fibrous cap and shoulders of the atheroma each predispose to plaque fissuring, subsequent plaque haemorrhage and disruption, and to coronary events.
PREVENTION OF PLAQUE DISRUPTION
Reduction of plasma LDL cholesterol might be expected to reduce the likelihood of fissuring because of the known favourable effects of LDL cholesterol reduction on the above predictors.2 5 A consequence of such protection against fissuring would be a decline in the frequency of abrupt progression to clinical events among patients in whom LDL cholesterol has been therapeutically reduced. Indeed, this has been the case. Figure 2 shows that in FATS there were 13 coronary and three peripheral vascular events (cardiac death, myocardial infarction, or revascularisation (PTCA or CABG) for refractory progressive ischaemia) among 15 patients. The decision for revascularisation was independent of the FATS trial investigators: it was made by private physicians who were blinded to randomisation and to the study lipid response. Analysis of the 13 coronary events among the 146 patients '7 showed that all clinical events were associated with a culprit coronary lesion located in the vascular distribution of the ischaemic electrocardiographic changes. Each had progressed significantly in severity from the baseline stenosis measurement to that at the time of the event. Furthermore, the progression of mild and moderately narrowed lesions to clinical events was virtually abolished by lipid-lowering therapy (fig 4) 
